Brainsway (BWAY) Stock: Buy, Sell, or Hold?
BWAY - Brainsway Ltd. American Depositary Shares
$11.98
-0.05 (-0.42%)
▼
5d:
+4.08%
30d:
-12.11%
90d:
-27.44%
BUY
HIGH Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 10, 2026
18d
Get Alerted When BWAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BWAY appears deeply undervalued. Market expects -17.9% annual earnings decline despite 60% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: BWAY appears deeply undervalued. Market expects -17.9% annual earnings decline despite 60% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.67
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$15.32
21.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BWAY is currently trading at $11.98, which is considered slightly low relative to its 30-day fair value range of $11.78 to $13.43. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.6) compared to its historical average (42.7). Remarkably, the market is currently pricing in an annual earnings decline of 17.9% over the next few years. This pessimistic expectation contrasts with the company's recent 59.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BWAY is in a downtrend. The price is approaching resistance at $12.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BWAY scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.27 (+60.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BWAY is in a downtrend. The price is approaching resistance at $12.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BWAY scores 88/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.27 (+60.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$11.78 -
$13.43
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (88/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 60.8% below Wall St target ($19.27)
- BULLISH: Bottoming setup score 88/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$11.78 -
$13.43
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$11.34
Resistance Level
$12.19
Current Trend
Downtrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
23.64
Wall Street Target
$19.27
(+60.8%)
Revenue Growth (YoY)
35.4%
Earnings Growth (YoY)
59.8%
Profit Margin
15.6%
Valuation Discount vs History
-17.9% cheaper
PE vs Historical
23.6 vs 42.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.9%
(market-implied from PE analysis)
1-Year Target
$10.78
(-10%)
2-Year Target
$9.70
(-19%)
3-Year Target
$8.73
(-27%)
3-Yr Target (if PE normalizes)
(PE: 24→43)
$15.77
(+32%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.6, Growth: 65.2%)
$40.43
(+238%)
Base:
(SPY PE: 19.9, Growth: 65.2%)
$33.96
(+184%)
Bear:
(PE: 16.9, Growth: 65.2%)
$28.87
(+141%)
📈
Valuation based on Current Earnings
Forward PE: 17.92 | Forward EPS (Implied): $0.67
Bull Case
$14.47
(+21%)
Analyst growth 15.0%, PE expands to 18.8
Base Case
$11.98
(0%)
Market implied 0.0%, PE stable at 17.9
Bear Case
$9.16
(-24%)
Severe decline -15.0%, PE contracts to 16.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.6 to 42.7
Stabilization Target:
$21.64
(+80.6%)
PE Expansion Potential:
+80.6%
Share & Embed Analysis
Last updated: October 22, 2026 6:34 AM ET
Data refreshes hourly during market hours. Next update: 7:34 AM
Data refreshes hourly during market hours. Next update: 7:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BWAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
31 analysts |
$59 | 50 HOLD |
|
SYK
Stryker Corporation |
STRONG BUY
29 analysts |
$363 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
29 analysts |
$105 | 43 HOLD |
|
AXGN
Axogen Inc |
STRONG BUY
12 analysts |
$54 | 75 BUY |
|
TNDM
Tandem Diabetes Care Inc |
BUY
25 analysts |
$28 | 54 HOLD |
